Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

INFORM

Financiado

Cerrado

Innovative Electrochemical Multiplex Biosensor for Detection and Quantification...

Innovative Electrochemical Multiplex Biosensor for Detection and Quantification of Clinically Relevant Circulating miRNAs Radical prostatectomy is currently the most used curative procedure in the treatment of localised prostate cancer (PCa). However, in 30-50% of interventioned patients Prostate Specific Antigen (PSA) increases on post-operatory, me... ver más

31/12/2021

UANTWERPEN

178K€

Presupuesto del proyecto: 178K€

Líder del proyecto

UNIVERSITEIT ANTWERPEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-12-31

MSCA-IF-2018: Individual Fellowships

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UANTWERPEN

178.32K€ | Lider

ACCION INTEGRAL ENERGETICA

225.79K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MoP-MiP Molecular Programming for MicroRNA profiling 1M€ Cerrado

LONGSENSE LONGSENSE A novel biosensor for lncRNA 150K€ Cerrado

AI-MICADIS Artificial Intelligence System for Multi Cancer Detection Su... 71K€ Cerrado

MIRCAB Validation of diagnostic and or prognostic miRNAs in triple... 71K€ Cerrado

SMART Self-Monitoring of Prostate cancer by Automated hybrid Recog... 173K€ Cerrado

BrEXo-Apt Non invasive and accurate diagnosis and treatment of breast... 188K€ Cerrado

Duración del proyecto: 32 meses Fecha Inicio: 2019-04-10
Fecha Fin: 2021-12-31

Líder del proyecto

UNIVERSITEIT ANTWERPEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 178K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Radical prostatectomy is currently the most used curative procedure in the treatment of localised prostate cancer (PCa). However, in 30-50% of interventioned patients Prostate Specific Antigen (PSA) increases on post-operatory, meaning that the cancer has spread. The rise in PSA is due to imprecision in preoperative staging, suggesting patients already had distant, undetectable disease. Another issue is that elevated serum PSA is not specific to malignant prostate disease, it cannot differentiate between indolent tumours or those that are/will become life threatening. Fatal cancer is most often due to metastatic disease but histopathological examination of biopsy or traditional imaging methods fail to detect the early disseminated circulating biological information highlighting the need for approaches that can detect biomarkers of cancer spreading at an early stage. Circulating amounts of non-coding microRNA (miRNA) have been shown to have a biological impact and to be clinically associated with cancer and are now seen as a new class of biomarkers that will allow earlier and more accurate diagnosis. The objective of INFORM is to develop an innovative electrochemical multiplex biosensor for detection and quantification of a panel of clinically relevant circulating miRNAs in intermediate-risk PCa patients that will be submitted to potentially curative surgery. By focusing on the development, optimisation and validation of a biosensor for miRNA profiling in PCa, discrimination of patients with local disease from those with more advanced PCa will be possible. The biosensor will rely on the selectivity of the sandwich assays and on the sensitivity of the photoelectrochemical detection to quantify, at the sub-fM level, circulating miRNAs that are associated with PCa. The quantification of these overexpressed miRNAs will lead to a better overall management of the disease and allow for a more informed decision by the medical doctor, providing personalised medicine.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores